BOSTON, Mass. (TheStreet) -- Here is June's calendar of important, potentially stock-moving biotech events:May 29-June 3 The American Urological Association annual meeting. June 2 FDA advisory panel meets to review AstraZeneca's ( AZN - Get Report) Numax for respiratory syncytial virus. June 3 BioDelivery Sciences ( BDSI) analyst/investor meeting. Johnson & Johnson ( JNJ) analyst/investors meeting. June 4-8 The American Society of Clinical Oncology (ASCO) annual meeting. Data presentation expected from Celldex Therapeutics ( CLDX - Get Report), Ziopharm ( ZIOP), Delcath Systems ( DCTH), Pfizer ( PFE - Get Report), Celgene ( CELG - Get Report) -- and too many other companies to mention here.
|More on Biotech 14 Biotech Stocks Facing FDA Approval|
June 16Genzyme ( GENZ) annual shareholder meeting. June 16-19 European League Against Rheumatism meeting. Lupus data presentations from Human Genome Sciences ( HGSI) and UCB/ Immunomedics ( IMMU). International Society for Stem Cell Research meeting. June 18 FDA advisory panel meets to review Boehringer Ingelheim's filbanserin for the treatment of female sexual dysfunction. The filbanserin panel could also impact Biosante Pharmaceuticals ( BPAX) and its competing female libido drug LibiGel, currently in phase III studies. June 24 FDA approval decision date for AstraZeneca's Numax for respiratory syncytial virus. Ligand Pharmaceuticals ( LGND) analyst/investor day. June 25-29 American Diabetes Association annual meeting. Sometime in June Phase III study results from Affymax's ( AFFY) anemia drug Hematide. -- Reported by Adam Feuerstein in Boston.
|More Biotech Stocks 14 Biotech Stocks Facing FDA Approval|